RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 10.4805

Change

+0.21 (+2.06)%

Market Cap

N/A

Volume

8.82K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-06 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

-0.15 (-0.36%)

USD 1.02B
SOXS Direxion Daily Semiconductor B..

+0.13 (+0.65%)

USD 0.72B
PSQ ProShares Short QQQ

-0.20 (-0.55%)

USD 0.55B
SPXU ProShares UltraPro Short S&P50..

-0.22 (-1.06%)

USD 0.51B
SDOW ProShares UltraPro Short Dow30

+0.37 (+0.85%)

USD 0.23B
YANG Direxion Daily FTSE China Bear..

-1.80 (-3.03%)

USD 0.18B
FNGD MicroSectors FANG+ Index -3X I..

-0.23 (-1.97%)

USD 0.17B
SPDN Direxion Daily S&P 500® Bear ..

-0.03 (-0.28%)

USD 0.15B
RWM ProShares Short Russell2000

+0.08 (+0.44%)

USD 0.14B
DOG ProShares Short Dow30

+0.08 (+0.32%)

USD 0.13B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.93% 20% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.93% 20% F 4% F
Trailing 12 Months  
Capital Gain -2.96% 98% N/A 23% F
Dividend Return 3.86% 79% B- 57% F
Total Return 0.90% 98% N/A 24% F
Trailing 5 Years  
Capital Gain -68.55% 69% C- 6% D-
Dividend Return 2.73% 68% D+ 7% C-
Total Return -65.82% 67% D+ 5% F
Average Annual (5 Year Horizon)  
Capital Gain 63.65% 40% F 95% A
Dividend Return 64.91% 40% F 95% A
Total Return 1.26% 60% D- 30% F
Risk Return Profile  
Volatility (Standard Deviation) 433.67% 62% D 3% F
Risk Adjusted Return 14.97% 47% F 31% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.